Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Anika Therapeutics (ANIK) Gains from Sales and Divestitures (2016 - 2025)

Anika Therapeutics (ANIK) has disclosed Gains from Sales and Divestitures for 14 consecutive years, with $317850.0 as the latest value for Q4 2025.

  • On a quarterly basis, Gains from Sales and Divestitures rose 2.06% to $317850.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $317850.0, a 2.06% increase, with the full-year FY2025 number at $317850.0, up 2.06% from a year prior.
  • Gains from Sales and Divestitures was $317850.0 for Q4 2025 at Anika Therapeutics, up from $106550.0 in the prior quarter.
  • In the past five years, Gains from Sales and Divestitures ranged from a high of $317850.0 in Q4 2025 to a low of $19125.0 in Q3 2022.
  • A 5-year average of $182275.9 and a median of $177611.0 in 2023 define the central range for Gains from Sales and Divestitures.
  • Peak YoY movement for Gains from Sales and Divestitures: surged 2150.33% in 2021, then plummeted 79.14% in 2022.
  • Anika Therapeutics' Gains from Sales and Divestitures stood at $91680.0 in 2021, then plummeted by 79.14% to $19125.0 in 2022, then skyrocketed by 1254.95% to $259134.0 in 2023, then increased by 20.19% to $311441.0 in 2024, then increased by 2.06% to $317850.0 in 2025.
  • Per Business Quant, the three most recent readings for ANIK's Gains from Sales and Divestitures are $317850.0 (Q4 2025), $106550.0 (Q2 2025), and $311441.0 (Q4 2024).